This article is more than 5 years old. Information may no longer be current.

Rivaroxaban shows promise in DVT, PE

Issue: January 2013

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ATLANTA — Jack E. Ansell, MD, chairman of medicine at Lenox Hill Hospital in New York, N.Y., discusses results of a pooled analysis of the EINSTEIN-PE and EINSTEIN-DVT trials. The findings showed rivaroxaban was noninferior to standard low-molecular–weight heparin and warfarin for the treatment of thromboembolic events.